Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase Ib/II study of amivantamab alone or in combination for head and neck squamous cell carcinoma
CTR20251076Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Janssen Pharmaceutical. Started May 2025; status: active.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20251076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251076.